Asia Pacific Antibody Drug Conjugates Market
市场规模（十亿美元）
CAGR :
% 
USD
1.77 Billion
USD
6.11 Billion
2023
2031
 Forecast Period |
2024 –2031 |
 Market Size (Base Year) |
USD 1.77 Billion |
 Market Size (Forecast Year) |
USD 6.11 Billion |
 CAGR |
% |
| Major Markets Players |
亞太抗體藥物偶聯物 (ADC) 市場細分、按產品（Enhertu、Kadcyla、Trodelvy、Polivy、Adcetris、Padcev、Besponsa、Elahere、Zylonta、Mylotarg、Tivdak 等）、抗原組成（HER2 受體、Trop-2、CD79in、CD30in 4、CD22、CD19、CD33、組織因子等）、抗體成分（第三代 ADC、第二代 ADC、第四代 ADC 和第一代 ADC）、連接子成分（可裂解連接子和不可裂解連接子）、細胞毒性有效載荷或彈頭成分（DNA損傷劑和微管破壞劑）、連接子技術（勝肽連接子、硫醚連接子、腙連接子和二硫鍵連接子）、偶聯技術（位點特異性結合和化學結合）、適應症（乳腺癌、血癌（白血病、淋巴瘤）、肺癌、婦科癌症、胃腸道癌症、泌尿生殖系統癌症等）、最終用戶（醫院、專科診所2031 年）
抗體藥物偶聯物（ADC）市場分析
2024年5月，根據美國國家癌症研究所發表的數據，預計2024年美國將新增200萬癌症病例，並有611,720人死亡。主要癌症包括乳癌、攝護腺癌、肺癌、大腸癌和黑色素瘤。攝護腺癌、肺癌和大腸癌將佔男性病例的 48%，而乳癌、肺癌和大腸癌將佔女性病例的 51%。年發病率為每十萬人440.5人，死亡率為每十萬人146.0人。在兒童和青少年（0-19 歲）中，預計將有 14,910 人確診，其中 1,590 人死亡。 FDA 批准的 ADC 數量不斷增加以及臨床試驗的不斷增加凸顯了市場的潛力。然而，製造成本高和生產流程複雜等挑戰可能會影響成長。總體而言，在技術進步和腫瘤治療應用日益普及的支持下，北美 ADC 市場有望大幅發展。
抗體藥物偶聯物（ADC）市場規模
2023 年亞太抗體藥物偶聯物 (ADC) 市場規模為 17.7 億美元，預計到 2031 年將達到 61.1 億美元，2024 年至 2031 年預測期內的複合年增長率為 16.7%。除了對市場價值、成長率、細分、地理覆蓋範圍和主要參與者等市場情景的洞察外，Data Bridge Market Research 策劃的市場報告還包括進出口分析、生產能力概覽、生產消費分析、價格趨勢分析、氣候變遷情境、供應鏈分析、價值鏈分析、原材料/消耗品概覽、供應商選擇標準、PESTLE 分析、波特分析和監管框架。
抗體藥物偶聯物（ADC）市場趨勢
“抗體-藥物偶聯物（ADC）技術的進展”
抗體藥物偶聯物 (ADC) 技術的進步透過提高癌症治療的治療效果和安全性，推動了亞太地區 ADC 市場的成長。關鍵的創新趨勢包括改進連接器，以實現穩定、精確的藥物輸送，以癌細胞為目標，同時保護健康組織。具有優化有效載荷和生物標記驅動的患者選擇的下一代 ADC 可確保治療惠及最受益的患者，並最大限度地減少副作用。此外，改進的製造流程降低了生產成本，增加了獲取途徑，並鼓勵對 ADC 開發進行更多投資，所有這些都有助於形成強大的產品線並擴大市場興趣。
報告範圍和抗體藥物偶聯物（ADC）市場細分
|
屬性 |
抗體藥物偶聯物（ADC）關鍵市場洞察 |
|
涵蓋的領域 |
|
|
覆蓋國家 |
日本、中國、印度、澳洲、新加坡和亞太其他地區 |
|
主要市場參與者 |
第一三共株式會社（日本）、羅氏公司（瑞士）、吉利德科學公司（美國）、安斯泰來製藥公司（日本）、武田製藥公司（日本）、輝瑞公司（美國）、艾伯維公司（美國）、ADC Therapeutics（瑞士）、安進公司（加州）、阿斯特捷利康公司（英國）、拜耳公司（德國）、Byondis（荷蘭）、衛材公司（日本）、葛蘭素史克公司（英國）、強生服務公司（美國）、Oxford BioTherapeutics（英國）、Remegen（中國）、賽諾菲公司（法國）、Atrad（美國）、美國）、賽諾菲公司（中國）、歐諾菲公司（中國）、Atragen Bioph)、賽諾菲公司（中國）、Atragen Bioph. |
|
市場機會 |
|
|
加值資料資訊集 |
除了對市場價值、成長率、細分、地理覆蓋範圍和主要參與者等市場情景的洞察之外，Data Bridge Market Research 策劃的市場報告還包括進出口分析、生產能力概覽、生產消費分析、價格趨勢分析、氣候變遷情景、供應鏈分析、價值鏈分析、原材料/消耗品概覽、供應商選擇標準、PESTLE 分析、波特分析和監管框架。 |
抗體藥物偶聯物（ADC）市場定義
抗體藥物偶聯物 (ADC) 是一種將抗體與強效抗癌藥物結合的標靶癌症療法。該抗體特異性地與癌細胞標記結合，將藥物直接輸送到癌細胞，同時最大限度地減少對健康細胞的影響。這種精確度減少了副作用並提高了藥物治療癌症的有效性。
抗體藥物偶聯物（ADC）市場動態
驅動程式
- 癌症發生率不斷上升
癌症發生率的上升極大地推動了北美抗體藥物偶聯物 (ADC) 市場的發展，增加了對有針對性的有效治療的需求。 ADC 透過將單株抗體與強效細胞毒藥物結合，可以精確靶向癌細胞，同時減少對健康組織的傷害。隨著癌症發生率的上升，製藥公司正在大力投資 ADC 技術，以滿足更個人化的治療需求，特別是針對具有挑戰性的癌症類型。癌症患者數量的成長加速了 ADC 臨床試驗、監管部門的批准和商業發布，進一步推動了 ADC 市場的發展。
例如，
2024年2月，根據世界衛生組織發表的文章預測，2022年全球將有2,000萬例新發癌症病例，970萬人死亡，5,350萬人在確診後五年內存活。最常見的是肺癌（250 萬例，12.4%），其次是乳癌（230 萬例，11.6%）、大腸癌（190 萬例，9.6%）、攝護腺癌（150 萬例，7.3%）和胃癌（97 萬例，4.9%）。每五人中就有一人會罹患癌症，預計到 2050 年新增病例將超過 3,500 萬，增幅達 77%。發病率的上升推動了標靶癌症治療市場的成長。
癌症發生率的上升顯著促進了北美 ADC 市場的發展，增加了對有針對性的、有效療法的需求。 ADC 能夠將強效治療直接傳遞給癌細胞，同時保護健康組織，因此作為一種有前景的解決方案而受到關注。日益加重的癌症負擔推動了 ADC 技術的研究、開發和投資，推動了新的進步並擴大了市場
- 抗體-藥物偶聯物（ADC）技術的進展
抗體藥物偶聯物 (ADC) 技術的進步透過提高癌症治療的治療效果和安全性，推動了全球 ADC 市場的成長。關鍵創新包括改進的連接器，以實現穩定、精確的藥物輸送，靶向癌細胞，同時保護健康組織。具有優化有效載荷和生物標記驅動的患者選擇的下一代 ADC 可確保治療惠及最受益的患者，並最大限度地減少副作用。此外，改進的製造流程降低了生產成本，增加了獲取途徑，並鼓勵對 ADC 開發進行更多投資，所有這些都有助於形成強大的產品線並擴大市場興趣。
例如，
2023年10月，根據《藥學報B》發表的文章，ADC研究的最新進展集中在開發更安全、更有效的有效載荷。關鍵進展包括更強的細胞毒藥物、用於精確遞送的穩定連接體以及 DNA 損傷劑和免疫調節劑等新型有效載荷。這些創新擴大了治療窗口，降低了脫靶毒性並提高了對抗抗藥性腫瘤的有效性，塑造了下一代 ADC。
增強的連接系統和有效的藥物有效載荷等創新提高了癌症治療的精確度和安全性。生物標記指導策略增強了患者針對性，以實現最佳療效。改進的製造技術使得 ADC 更易於獲取且更具成本效益，從而吸引了投資並擴大了治療選擇。總體而言，這些進步提高了 ADC 的有效性，並刺激了市場成長和製藥業的興趣
機會
抗體藥物偶聯物（ADCS）腫瘤學研發管線不斷拓展
抗體藥物偶聯物（ADC）的腫瘤學產品線正在迅速擴展，具有巨大的市場潛力。在腫瘤生物學的進步和標靶治療需求的推動下，許多 ADC 候選藥物正處於不同的開發階段。
製藥和生物技術公司正在大力投資新的 ADC，以提高一系列癌症（包括實體腫瘤和血液系統惡性腫瘤）的療效和安全性。連接技術、有效載荷和抗體工程方面的創新正在產生更有效、毒性更小的 ADC，拓寬治療選擇並吸引投資者的興趣。
例如，
2024年8月，根據強生創新有限責任公司發表的文章，強生不斷增長的抗體藥物偶聯物（ADC）療法產品線和積極的合作表明了對ADC領域的堅定承諾。他們強調創新、安全和有效的癌症治療，展現了 ADC 的變革潛力。這些措施促進了產業合作，增強了發展和可及性，並為北美 ADC 市場創造了巨大的成長機會。
- 增加對癌症研究的投資
增加對癌症研究的投資為全球抗體藥物偶聯物 (ADC) 市場的成長提供了重大機會。由於政府、私人組織和慈善機構優先考慮有效的癌症治療，這些資金對於推動創新的 ADC 療法至關重要。
這些投資使研究人員能夠加深對腫瘤生物學和藥物作用機制的理解，這對於開發更有針對性和更有效的 ADC 至關重要。此外，增加資金可以促進更大規模、更多樣化的臨床試驗，提高對患者反應的了解，並加快有前景的 ADC 候選藥物的評估和批准流程。
例如，
2024年10月，根據UKRI發表的文章，英國創新署和OLS將在「生命科學願景癌症任務」的「先進精準醫療」競賽下，向六個項目投資519萬美元。這筆巨額資金凸顯了人們對癌症研究和開發的日益增長的投入。這些投資為包括抗體藥物偶聯物（ADC）在內的創新療法鋪平了道路，為全球 ADC 市場的成長創造了寶貴的機會。
限制/挑戰
- 開發成本高且製造複雜
研究所需的大量投資（包括創新的連接體設計、選擇細胞毒性劑和優化結合技術）大大增加了成本。複雜的製造過程需要精確的藥物抗體連接和嚴格的品質控制，這進一步增加了費用。此外，安全高效生產所需的專門設施和設備增加了財務負擔，使小型生物技術公司難以進行 ADC 開發，並限制大型公司一次只能進行幾個專案。因此，儘管 ADC 提供了有前景的標靶癌症治療方法，但這些問題限制了市場成長和新治療方法的引入。
例如，
2024年7月，據《抗體藥物偶聯物雜誌》刊登的文章稱，百時美施貴寶公司（BMS）支付了8億美元的預付款，以授權Systimmune公司的EGFR x HER3雙特異性ADC BL-B01D1（Zalontamab brengitecan），該藥物目前在美國處於13期臨床，該藥物目前在中國處於13期臨床，該藥物目前在中國處於13期臨床，該藥物目前處於13期臨床，該藥物目前處於13期臨床，該藥物目前在中國處於13期臨床，該藥物目前處於13期臨床，該藥物目前處於13期臨床，該藥物目前在中國處於13期臨床，在中國處於臨床階段。雖然 BL-B01D1 在經過大量預先治療的轉移性實體瘤中表現出良好的安全性和有效性，但高昂的投資成本令人擔憂。此外，開發雙特異性 ADC 也面臨挑戰，例如選擇合適的抗體形式，通常需要創建兩個穩定的細胞系。這種複雜性增加了製造成本並使檢測開發變得複雜
高昂的開發成本和製造複雜性嚴重阻礙了北美抗體-藥物偶聯物 (ADC) 市場的成長。研究所需的大量資金投入和複雜的製造流程導致生產費用增加。這種複雜性不僅需要嚴格的品質控制措施，還需要專門的設施和設備，進一步加劇資源緊張。因此，小型生物技術公司可能不願意進入市場，而大型公司也可能會限制其 ADC 計畫。
- 抗體藥物偶聯物的安全性和毒性問題
安全性和毒性問題是全球抗體藥物偶聯物 (ADC) 市場成長的主要限制因素。儘管 ADC 的設計目標是針對癌細胞，但由於其強大的細胞毒性負荷，可能會對健康組織產生不利影響，導致全身毒性和副作用，如嗜中性球減少症和器官特異性毒性。此外，不可預測的免疫反應可能引起過敏反應或免疫原性，從而限制其在某些患者群體中的使用。脫靶效應的風險，即 ADC 影響具有相似抗原的非癌細胞，進一步使治療複雜化。
例如，
2021年6月，根據愛思唯爾發布的新聞稿，脫靶毒性是抗體-藥物偶聯物（ADC）劑量限制性副作用的主要原因，主要是由於連接體-藥物不穩定和過早有效載荷釋放。這種狹窄的治療指數需要在臨床前和臨床階段進行徹底的安全評估。改進測試方法和了解安全性對於優化 ADC 的治療潛力至關重要。
安全性和毒性問題對全球 ADC 市場構成重大挑戰，因為強效細胞毒性藥物可能導致嚴重的副作用，包括血液疾病和器官特異性毒性。免疫反應和脫靶效應的風險使其安全使用變得複雜，需要嚴格的臨床測試和監管監督。
抗體藥物偶聯物（ADC）市場範圍
市場根據產品、抗原成分、抗體成分、連接體成分、細胞毒性有效載荷或彈頭成分、連接體技術、結合技術、適應症、最終用戶和分銷管道進行細分。這些細分市場之間的成長將幫助您分析行業中成長微弱的細分市場，並為用戶提供有價值的市場概覽和市場洞察，幫助他們做出策略決策，確定核心市場應用。
產品
- 恩赫圖
- 卡德西拉
- 替換
- 下一個
- 瀑布
- 不負責任
- 埃拉赫
- 澤隆塔
- 麥洛塔格
- 蒂夫達克
- 其他的
抗原成分
- HER2受體
- Too-2
- CD79B
- CD30
- 連接蛋白 4
- CD22
- CD19
- CD33
- 組織因素
- 其他的
抗體成分
- 第三代ADC
- 第二代ADC
- 第四代ADC
- 第一代ADC
連結器組件
- 可裂解接頭
- 基於勝肽
- 酸敏感或酸不穩定
- 穀胱甘肽敏感二硫化物
- 不可裂解接頭
細胞毒性有效載荷或彈頭部件
- DNA損傷劑
- 喜樹鹼
- 卡利車黴素
- 吡咯並苯二氮平類
- 微管破壞劑
- 奧瑞司他
- 美登木素類
聯創科技
- 勝肽連接子
- 硫醚連接體
- 腙連接子
- 二硫鍵連接子
共軛技術
- 位點特異性結合
- 化學共軛
適應症
- 乳癌
- 血癌（白血病、淋巴瘤）
- 肺癌
- 婦科癌症
- 胃腸道癌症
- 泌尿生殖系統癌症
- 其他的
最終用戶
- 醫院
- 專業中心
- 診所
- 門診中心
- 家庭醫療保健
- 其他的
分銷管道
- 直接招標
- 零售
- 醫院藥房
- 零售藥局
- 網路藥局
- 其他的
抗體藥物偶聯物（ADC）市場區域分析
對市場進行分析，並按國家、產品、抗原成分、抗體成分、連接體成分、細胞毒性有效載荷或彈頭成分、連接體技術、結合技術、適應症、最終用戶和分銷渠道提供市場規模洞察和趨勢，如上所述。
市場涵蓋的國家包括日本、中國、印度、澳洲、新加坡和亞太其他地區。
日本憑藉其先進的醫療保健基礎設施、對創新醫療設備的高需求以及對品質和患者護理的高度重視，預計將在市場中佔據主導地位。
由於先進醫療技術的採用日益增多、慢性病患病率不斷上升以及對具有成本效益的長期血管通路解決方案的日益重視，日本預計將成為成長最快的國家。
報告的國家部分還提供了影響個別市場因素以及影響市場當前和未來趨勢的國內市場監管變化。下游和上游價值鏈分析、技術趨勢和波特五力分析、案例研究等數據點是用於預測各國市場情景的一些指標。此外，在對國家數據進行預測分析時，還考慮了亞太品牌的存在和可用性，以及由於來自本地和國內品牌的大量或稀缺的競爭而面臨的挑戰、國內關稅和貿易路線的影響。
抗體藥物偶聯物（ADC）市場份額
市場競爭格局提供了競爭對手的詳細資訊。詳細資訊包括公司概況、公司財務狀況、收入、市場潛力、研發投資、新市場計劃、亞太地區業務、生產基地和設施、生產能力、公司優勢和劣勢、產品發布、產品寬度和廣度、應用優勢。以上提供的數據點僅與公司對市場的關注有關。
抗體藥物偶聯物 (ADC) 市場領導者包括：
- 第一三共株式會社（日本）
- F. Hoffmann-La Roche Ltd（基因泰克）（瑞士）
- 吉利德科學公司（美國）
- 安斯泰來製藥公司（日本）
- 武田（日本）
- 輝瑞公司（美國）
- Abbvie（美國）
- ADC Therapeutics（瑞士）
- 安進公司（美國）
- 阿斯特捷利康（英國）
- 拜耳（德國）
- Byondis（荷蘭）
- 衛材株式會社（日本）
- 葛蘭素史克公司（英國）
- 強生服務公司（美國）
- 牛津大型治療公司（英國）
- 顫抖（中國）
- 賽諾菲（法國）
- Sutra Biopharma（美國）
抗體藥物偶聯物（ADC）市場的最新發展
- 2024年10月，第一三共和阿斯特捷利康的ENHERTU在中國獲得有條件批准，成為首個針對HER2突變轉移性非小細胞肺癌（NSCLC）成年患者的HER2標靶療法。此核准是基於 DESTINY-Lung02 和 DESTINY-Lung05 研究的積極結果，凸顯了 ENHERTU 對先前接受過治療的患者的療效。這是恩赫圖在中國針對多種腫瘤類型的第四個適應症，增強了兩家公司的腫瘤產品組合，並解決了肺癌治療領域尚未滿足的重大需求
- 2024 年 8 月，拜耳與 NextRNA Therapeutics 宣布達成合作與許可協議，共同開發針對腫瘤領域長鏈非編碼 RNA (lncRNA) 的小分子療法，為疾病治療中破壞 lncRNA-RBP 相互作用提供一種新方法
- 2023 年 3 月，羅氏宣布與禮來合作開發 Elecsys 澱粉樣蛋白血漿面板。這項創新的血液檢測旨在促進阿茲海默症的早期診斷，解決重大障礙並改善患者及時治療的機會
- 2022年1月，羅氏推出了創新手持血糖管理設備cobas pulse系統。它將先進的數位功能與用戶友好的設計相結合，簡化了醫療專業人員的工作流程，並增強了各種環境下的患者護理
- 2024 年 6 月，武田擴大了與健康夥伴組織 (PIH) 的合作夥伴關係，以改善馬薩諸塞州的健康公平。該計劃將建立健康公平實踐社區，增強地方衛生部門的能力，並為社區衛生工作者創造更多機會
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 PESTEL ANALYSIS
5 COST STRUCTURE ANALYSIS OF ANTIBODY-DRUG CONJUGATE (ADC) MANUFACTURING
5.1 ANTIBODIES
5.1.1 OVERVIEW OF ANTIBODY PRODUCTION
5.1.1.1 In-house vs. Outsourced:
5.1.2 ANTIBODY PRICING FACTORS
5.2 LINKERS
5.2.1 ROLE AND TYPES OF LINKERS
5.2.1.1 Cost Impact by Linker Type:
5.3 CYTOTOXIC AGENTS
5.3.1 COST CONSIDERATIONS:
5.3.2 BUFFERS AND SOLVENTS
5.4 COST BREAKDOWN BY MANUFACTURING STAGE
5.4.1 PRE-PRODUCTION COSTS
5.4.2 CONJUGATION PROCESS
5.4.3 PURIFICATION AND FILTRATION
5.4.4 QUALITY CONTROL
5.5 COST PROJECTIONS AND PRICING TRENDS (2024–2030)
5.5.1 PROJECTED COST FLUCTUATIONS
5.5.2 COST IMPACT OF SCALABILITY
5.6 SUPPLIER AND GEOGRAPHIC PRICING TRENDS
5.6.1 GEOGRAPHIC COST VARIATIONS
5.6.2 SUPPLIER ANALYSIS
5.6.3 CONCLUSION
6 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE OF CANCER
7.1.2 ADVANCES IN ANTIBODY-DRUG CONJUGATE (ADC) TECHNOLOGY
7.1.3 INCREASING DEMAND FOR TARGETED THERAPIES
7.1.4 ADVANCEMENTS IN PROTEOMICS AND GENOMICS RESEARCH
7.2 RESTRAINTS
7.2.1 HIGH DEVELOPMENT COST & MANUFACTURING COMPLEXITIES
7.2.2 SAFETY AND TOXICITY ISSUES OF ANTIBODY DRUG CONJUGATES
7.3 OPPORTUNITIES
7.3.1 GROWING ONCOLOGY PIPELINE FOR ANTIBODY DRUG CONJUGATES (ADCS)
7.3.2 INCREASING INVESTMENT IN CANCER RESEARCH
7.3.3 INCREASING COLLABORATION WITH RESEARCH INSTITUTIONS FOR ANTIBODY DRUG CONJUGATES
7.4 CHALLENGES
7.4.1 CLINICAL TRIAL FAILURES FOR ANTIBODY DRUG CONJUGATES DEVELOPMENT
7.4.2 LENGTHY CLINICAL TRIALS AND DEVELOPMENT PHASES
8 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT
8.1 OVERVIEW
8.2 ENHERTU
8.3 KADCYLA
8.4 TRODELVY
8.5 POLIVY
8.6 ADCETRIS
8.7 PADCEV
8.8 BESPONSA
8.9 ELAHERE
8.1 ZYLONTA
8.11 MYLOTARG
8.12 TIVDAK
8.13 OTHERS
9 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT
9.1 OVERVIEW
9.2 HER2 RECEPTOR
9.3 TROP-2
9.4 CD79B
9.5 CD30
9.6 NECTIN 4
9.7 CD22
9.8 CD19
9.9 CD33
9.1 TISSUE FACTORS
9.11 OTHERS
10 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT
10.1 OVERVIEW
10.2 THIRD GENERATION ADCS
10.3 SECOND GENERATION ADCS
10.4 FOURTH GENERATION ADCS
10.5 FIRST GENERATION ADCS
11 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT
11.1 OVERVIEW
11.2 CLEAVABLE LINKERS
11.2.1 PEPTIDE BASED
11.2.2 ACID SENSITIVE OR ACID LABILE
11.2.3 GLUTATHIONE SENSITIVE DISULFIDE
11.3 NON CLEAVABLE LINKERS
12 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT
12.1 OVERVIEW
12.2 DNA DAMAGING AGENTS
12.2.1 CAMPTOTHECIN
12.2.2 CALICHEAMICIN
12.2.3 PYRROLOBENZODIAZEPINES
12.3 MICROTUBULE DISRUPTING AGENTS
12.3.1 AURISTATIN
12.3.2 MAYTANSINOIDS
13 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY
13.1 OVERVIEW
13.2 PEPTIDE LINKERS
13.3 THIOETHER LINKERS
13.4 HYDRAZONE LINKERS
13.5 DISULFIDE LINKERS
14 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY
14.1 OVERVIEW
14.2 SITE-SPECIFIC CONJUGATION
14.3 CHEMICAL CONJUGATION
15 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION
15.1 OVERVIEW
15.2 BREAST CANCER
15.3 BLOOD CANCER (LEUKEMIA, LYMPHOMA)
15.4 LUNG CANCER
15.5 GYNECOLOGICAL CANCER
15.6 GASTROINTESTINAL CANCER
15.7 GENITOURINARY CANCER
15.8 OTHERS
16 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITALS
16.3 SPECIALTY CENTER
16.4 CLINICS
16.5 AMBULATORY CENTERS
16.6 HOME HEALTHCARE
16.7 OTHERS
17 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 DIRECT TENDERS
17.3 RETAIL SALES
17.3.1 HOSPITAL PHARMACY
17.3.2 RETAIL PHARMACY
17.3.3 ONLINE PHARMACY
17.4 OTHERS
18 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION
18.1 ASIA-PACIFIC
18.1.1 JAPAN
18.1.2 CHINA
18.1.3 INDIA
18.1.4 AUSTRALIA
18.1.5 SINGAPORE
18.1.6 REST OF ASIA-PACIFIC
19 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC): COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: GLOBAL
20 SWOT ANALYSIS
21 COMPANY PROFILES
21.1 DAIICHI SANKYO, INC.
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 PRODUCT PORTFOLIO
21.1.4 RECENT DEVELOPMENT
21.2 F. HOFFMANN-LA ROCHE LTD
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 PRODUCT PORTFOLIO
21.2.4 RECENT DEVELOPMENT
21.3 GILEAD SCIENCES, INC.
21.3.1 COMPANY SNAPSHOT
21.3.2 REVENUE
21.3.3 PRODUCT PORTFOLIO
21.3.4 RECENT DEVELOPMENT
21.4 ASTELLAS PHARMA INC.
21.4.1 COMPANY SNAPSHOT
21.4.2 REVENUE ANALYSIS
21.4.3 PRODUCT PORTFOLIO
21.4.4 RECENT DEVELOPMENT
21.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED
21.5.1 COMPANY SNAPSHOT
21.5.2 REVENUE ANALYSIS
21.5.3 PRODUCT PORTFOLIO
21.5.4 RECENT DEVELOPMENT
21.6 ABBVIE INC.
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENT
21.7 ADC THERAPEUTICS SA
21.7.1 6.1 COMPANY SNAPSHOT
21.7.2 REVENUE ANALYSIS
21.7.3 PRODUCT PORTFOLIO
21.7.4 RECENT DEVELOPMENT
21.8 AMGEN, INC.
21.8.1 COMPANY SNAPSHOT
21.8.2 REVENUE ANALYSIS
21.8.3 PRODUCT PORTFOLIO
21.8.4 RECENT DEVELOPMENT
21.9 ASTRAZENECA
21.9.1 COMPANY SNAPSHOT
21.9.2 REVENUE ANALYSIS
21.9.3 PRODUCT PORTFOLIO
21.9.4 RECENT DEVELOPMENT
21.1 BAYER
21.10.1 COMPANY SNAPSHOT
21.10.2 REVENUE ANALYSIS
21.10.3 PRODUCT PORTFOLIO
21.10.4 RECENT DEVELOPMENT
21.11 BYONDIS
21.11.1 COMPANY SNAPSHOT
21.11.2 PRODUCT PORTFOLIO
21.11.3 RECENT DEVELOPMENT
21.12 EISAI INC
21.12.1 COMPANY SNAPSHOT
21.12.2 REVENUE ANALYSIS
21.12.3 PRODUCT PORTFOLIO
21.12.4 RECENT DEVELOPMENT
21.13 GSK PLC
21.13.1 COMPANY SNAPSHOT
21.13.2 REVENUE ANALYSIS
21.13.3 PRODUCT PORTFOLIO
21.13.4 RECENT DEVELOPMENT
21.14 JOHNSON & JOHNSON SERVICES, INC.
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE ANALYSIS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENT
21.15 OXFORD BIOTHERAPEUTICS
21.15.1 COMPANY SNAPSHOT
21.15.2 PRODUCT PORTFOLIO
21.15.3 RECENT DEVELOPMENT
21.16 PFIZER INC.
21.16.1 COMPANY SNAPSHOT
21.16.2 REVENUE ANALYSIS
21.16.3 PRODUCT PORTFOLIO
21.16.4 RECENT UPDATES
21.17 REMEGEN
21.17.1 COMPANY SNAPSHOT
21.17.2 PRODUCT PORTFOLIO
21.17.3 RECENT DEVELOPMENTS
21.18 SANOFI
21.18.1 COMPANY SNAPSHOT
21.18.2 REVENUE ANALYSIS
21.18.3 PRODUCT PORTFOLIO
21.18.4 RECENT DEVELOPMENT
21.19 SUTRO BIOPHARMA, INC.
21.19.1 COMPANY SNAPSHOT
21.19.2 REVENUE ANALYSIS
21.19.3 PRODUCT PORTFOLIO
21.19.4 RECENT UPDATES
22 QUESTIONNAIRE
23 RELATED REPORTS
表格列表
TABLE 1 PROJECTED PRICE CHANGE (2024–2030)
TABLE 2 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 3 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 4 ASIA-PACIFIC ENHERTU IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 5 ASIA-PACIFIC KADCYLA IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 6 ASIA-PACIFIC TRODELVY IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 7 ASIA-PACIFIC POLIVY IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 8 ASIA-PACIFIC ADCETRIS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 9 ASIA-PACIFIC PADCEV IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 10 ASIA-PACIFIC BESPONSA IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 11 ASIA-PACIFIC ELAHERE IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 12 ASIA-PACIFIC ZYLONTA IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 13 ASIA-PACIFIC MYLOTARG IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 14 ASIA-PACIFIC TIVDAK IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 15 ASIA-PACIFIC OTHERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 16 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 17 ASIA-PACIFIC HER2 RECEPTOR IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 18 ASIA-PACIFIC TROP-2 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 19 ASIA-PACIFIC CD79B IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 20 ASIA-PACIFIC CD30 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 21 ASIA-PACIFIC NECTIN 4 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 22 ASIA-PACIFIC CD22 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 23 ASIA-PACIFIC CD19 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 24 ASIA-PACIFIC CD33 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 25 ASIA-PACIFIC TISSUE FACTORS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 26 ASIA-PACIFIC OTHERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 27 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 28 ASIA-PACIFIC THIRD GENERATION ADCS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 29 ASIA-PACIFIC SECOND GENERATION ADCS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 30 ASIA-PACIFIC FOURTH GENERATION ADCS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 31 ASIA-PACIFIC FIRST GENERATION ADCS IN OPHTHALMOLOGY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 32 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 33 ASIA-PACIFIC CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 34 ASIA-PACIFIC CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 35 ASIA-PACIFIC NON CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 36 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 37 ASIA-PACIFIC DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 38 ASIA-PACIFIC DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 39 ASIA-PACIFIC MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 40 ASIA-PACIFIC MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 41 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 42 ASIA-PACIFIC PEPTIDE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 43 ASIA-PACIFIC THIOETHER LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 44 ASIA-PACIFIC HYDRAZONE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 45 ASIA-PACIFIC DISULFIDE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 46 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 47 ASIA-PACIFIC SITE-SPECIFIC CONJUGATION IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 48 ASIA-PACIFIC CHEMICAL CONJUGATION IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 49 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 50 ASIA-PACIFIC BREAST CANCER IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 51 ASIA-PACIFIC BLOOD CANCER (LEUKEMIA, LYMPHOMA) IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 52 ASIA-PACIFIC LUNG CANCER IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 53 ASIA-PACIFIC GYNECOLOGICAL CANCER IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 54 ASIA-PACIFIC GASTROINTESTINAL CANCER IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 55 ASIA-PACIFIC GENITOURINARY CANCER IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 56 ASIA-PACIFIC OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 57 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 58 ASIA-PACIFIC HOSPITALS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 59 ASIA-PACIFIC SPECIALTY CENTERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 60 ASIA-PACIFIC CLINICS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 61 ASIA-PACIFIC AMBULATORY CENTERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 62 ASIA-PACIFIC HOME HEALTHCARE IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 63 ASIA-PACIFIC OTHERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 64 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 65 ASIA-PACIFIC DIRECT TENDERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 66 ASIA-PACIFIC RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 67 ASIA-PACIFIC RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 68 ASIA-PACIFIC OTHERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 69 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 70 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 71 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 72 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)
TABLE 73 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 74 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 75 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 76 ASIA-PACIFIC CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 77 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 78 ASIA-PACIFIC DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 79 ASIA-PACIFIC MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 80 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 81 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 82 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 83 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 84 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 85 ASIA-PACIFIC RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 86 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 87 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 88 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)
TABLE 89 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 90 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 91 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 92 JAPAN CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 93 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 94 JAPAN DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 95 JAPAN MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 96 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 97 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 98 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 99 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 100 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 101 JAPAN RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 102 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 103 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 104 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)
TABLE 105 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 106 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 107 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 108 CHINA CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 109 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 110 CHINA DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 111 CHINA MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 112 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 113 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 114 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 115 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 116 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 117 CHINA RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 118 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 119 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 120 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)
TABLE 121 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 122 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 123 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 124 INDIA CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 125 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 126 INDIA DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 127 INDIA MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 128 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 129 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 130 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 131 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 132 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 133 INDIA RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 134 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 135 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 136 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)
TABLE 137 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 138 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 139 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 140 AUSTRALIA CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 141 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 142 AUSTRALIA DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 143 AUSTRALIA MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 144 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 145 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 146 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 147 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 148 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 149 AUSTRALIA RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 150 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 151 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 152 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)
TABLE 153 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 154 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 155 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 156 SINGAPORE CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 157 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 158 SINGAPORE DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 159 SINGAPORE MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 160 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 161 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 162 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 163 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 164 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 165 SINGAPORE RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 166 REST OF ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 167 REST OF ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 168 REST OF ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)
图片列表
FIGURE 1 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: SEGMENTATION
FIGURE 11 EXECUTIVE SUMMARY
FIGURE 12 STRATEGIC DECISIONS
FIGURE 13 RISING INCIDENCE OF CANCER IS DRIVING THE GROWTH OF THE ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET FROM 2024 TO 2031
FIGURE 14 THE PRODUCT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET IN 2024 AND 2031
FIGURE 15 DROC
FIGURE 16 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY PRODUCT, 2023
FIGURE 17 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY PRODUCT, 2024-2031 (USD MILLION)
FIGURE 18 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY PRODUCT, CAGR (2024-2031)
FIGURE 19 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 20 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIGEN COMPONENT, 2023
FIGURE 21 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIGEN COMPONENT, 2024-2031 (USD MILLION)
FIGURE 22 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIGEN COMPONENT, CAGR (2024-2031)
FIGURE 23 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIGEN COMPONENT, LIFELINE CURVE
FIGURE 24 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIBODY COMPONENT, 2023
FIGURE 25 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIBODY COMPONENT, 2024-2031 (USD MILLION)
FIGURE 26 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIBODY COMPONENT, CAGR (2024-2031)
FIGURE 27 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIBODY COMPONENT, LIFELINE CURVE
FIGURE 28 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKERS COMPONENT, 2023
FIGURE 29 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKERS COMPONENT, 2024-2031 (USD MILLION)
FIGURE 30 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKERS COMPONENT, CAGR (2024-2031)
FIGURE 31 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKERS COMPONENT, LIFELINE CURVE
FIGURE 32 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2023
FIGURE 33 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2024-2031 (USD MILLION)
FIGURE 34 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, CAGR (2024-2031)
FIGURE 35 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, LIFELINE CURVE
FIGURE 36 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKER TECHNOLOGY, 2023
FIGURE 37 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKER TECHNOLOGY, 2024-2031 (USD MILLION)
FIGURE 38 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKER TECHNOLOGY, CAGR (2024-2031)
FIGURE 39 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKER TECHNOLOGY, LIFELINE CURVE
FIGURE 40 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CONJUGATION TECHNOLOGY, 2023
FIGURE 41 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CONJUGATION TECHNOLOGY, 2024-2031 (USD MILLION)
FIGURE 42 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CONJUGATION TECHNOLOGY, CAGR (2024-2031)
FIGURE 43 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CONJUGATION TECHNOLOGY, LIFELINE CURVE
FIGURE 44 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY INDICATION, 2023
FIGURE 45 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY INDICATION, 2024-2031 (USD MILLION)
FIGURE 46 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY INDICATION, CAGR (2024-2031)
FIGURE 47 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 48 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY END USER, 2023
FIGURE 49 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 50 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY END USER, CAGR (2024-2031)
FIGURE 51 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY END USER, LIFELINE CURVE
FIGURE 52 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 53 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 54 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 55 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 56 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET: SNAPSHOT (2023)
FIGURE 57 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC): COMPANY SHARE 2023 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
